- $37.66m
- -$16.42m
- $20.60m
Brief: Scynexis Announces Appointment Of Sanjay Subramanian As Chief Financial Officer
Scynexis Inc Reports Results For The Quarter Ended June 30: Earnings Summary
Scynexis Q2 swings to profit on warrant adjustment; advances drug studies
Scynexis Inc Expected To Post A Loss Of 51 Cents A Share: Earnings Preview
NASDAQ RESUMED AT 12:04 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:56 AM
NASDAQ RESUMED AT 11:54 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 11:47 AM
Brief: Scynexis Initiates Phase 1 Study Of Scy-770, A Novel Ampk Activator For The Treatment Of Autosomal Dominant Polycystic Kidney Disease (Adpkd)
NASDAQ TRADE HALT REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 03:28 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Scynexis Q1 net loss widens on higher R&D costs
Brief: Scynexis Q1 Operating Expenses USD 16.939 Million
Brief: SCYNEXIS Receives FDA Qualified Infectious Disease Product And Fast Track Designations For SCY-247
Brief: Scynexis Granted 180-Day Extension By Nasdaq To Regain Compliance With Minimum Bid Price Requirement
Brief: Scynexis completes transfer of Brexafemme New Drug Application To GSK
Antifungal drug developer Scynexis's Q3 net loss widens